Promising combo tackles rare lung cancer in small trial
NCT ID NCT05375734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, tislelizumab and anlotinib, in 29 people with advanced pulmonary pleomorphic carcinoma, a rare and aggressive lung cancer. The goal was to see if the combo could shrink tumors or slow the disease. Participants had stage III or IV cancer that could not be surgically removed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Afiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Triple therapy takes on rare, aggressive kidney cancer
- Bladder cancer drug delivered directly: a new hope for BCG failures
- Immunotherapy combo may boost rectal cancer treatment
- New cocktail aims to make immunotherapy work for common colorectal cancer
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors